Quifenadine is a non-sedating antihistamine with a long duration of action. It is a selective antagonist of the histamine H1 receptor, which is involved in allergic reactions. Quifenadine has been shown to be effective in treating allergic rhinitis, urticaria, and other allergic conditions. It is well-tolerated and has a low incidence of side effects. Quifenadine is synthesized in a multi-step process starting from 4-chloro-3-nitrobenzoic acid. It is studied for its potential use in treating allergic diseases, and also in treating other conditions such as Alzheimer's disease and cancer.'
quifenadine: Russian drug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
WS 9326A: from Streptomyces violaceusniger No. 9326; tachykinin receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 65600 |
| CHEMBL ID | 1187694 |
| CHEBI ID | 134746 |
| SCHEMBL ID | 1813124 |
| SCHEMBL ID | 15292380 |
| MeSH ID | M0063523 |
| PubMed CID | 168012504 |
| MeSH ID | M0063523 |
| Synonym |
|---|
| quifenadinum [inn-latin] |
| quifenadino [inn-spanish] |
| 1-azabicyclo(2.2.2)octane-3-methanol, alpha,alpha-diphenyl- |
| quifenadine |
| alpha,alpha-diphenyl-3-chinuclidinylmethanol |
| benzhydrol, alpha-(3-quinuclidinyl)- |
| alpha,alpha-diphenyl-3-quinuclidinemethanol |
| brn 1542055 |
| quifenadine [inn] |
| 3-quinuclidinemethanol, alpha,alpha-diphenyl- |
| STK697937 |
| 1-azabicyclo[2.2.2]oct-3-yl(diphenyl)methanol |
| OPREA1_250552 |
| NCGC00160492-01 |
| CHEBI:134746 |
| 1-azabicyclo[2.2.2]octan-3-yl(diphenyl)methanol |
| AKOS001668833 |
| 10447-39-9 |
| w9a18rj49b , |
| quifenadino |
| unii-w9a18rj49b |
| quifenadinum |
| dtxsid6046187 , |
| tox21_111852 |
| dtxcid4026187 |
| cas-10447-39-9 |
| quifenadine (inn) |
| D10230 |
| CHEMBL1187694 |
| AG-205/05218021 |
| BBL022956 |
| .alpha.,.alpha.-diphenyl-3-quinuclidinemethanol |
| quifenadine [who-dd] |
| (3-quinuclidinyl)diphenyl carbinol hydrochloride |
| AB00637982-07 |
| AKOS022061528 |
| diphenyl(quinuclidin-3-yl)methanol |
| smr002499074 |
| MLS006011470 |
| SCHEMBL1813124 |
| 3-quinuclidinemethanol, .alpha.,.alpha.-diphenyl- |
| benzhydrol, .alpha.-(3-quinuclidinyl)- |
| fencarol [as hydrochloride] |
| PZMAHNDJABQWGS-UHFFFAOYSA-N |
| phencarol [as hydrochloride] |
| SCHEMBL15292380 |
| NCGC00160492-02 |
| phencarol; fenatin; fencarol |
| BCP21301 |
| Q4497981 |
| {1-azabicyclo[2.2.2]octan-3-yl}diphenylmethanol |
| VS-07290 |
| DB13713 |
| ws 9326a |
| AKOS040747582 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| diarylmethane | Any compound containing two aryl groups connected by a single C atom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Quifenadine H1-Antihistamine Action | 8 | 7 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 29.8554 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| AR protein | Homo sapiens (human) | Potency | 26.6032 | 0.0002 | 21.2231 | 8,912.5098 | AID743040 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 29.8493 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 3.5481 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 28.7466 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 18.1056 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 16.7855 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.69) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (11.11%) | 5.53% |
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (7.41%) | 6.00% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (81.48%) | 84.16% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||